70 citations
,
September 2017 in “Expert opinion on therapeutic patents” The review suggests that while many AKR1C3 inhibitors show promise for treating certain cancers, more research is needed to confirm their effectiveness in humans.
46 citations
,
September 2011 in “Journal of Endocrinology” Natural 5α-reduced glucocorticoids might be anti-inflammatory with fewer side effects than current options.
13 citations
,
August 2007 in “Bioorganic & medicinal chemistry letters” A new compound effectively inhibits human 5α-reductase 1.
August 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Certain hydroxycinnamate derivatives may effectively inhibit enzymes linked to hair loss with low toxicity.
5 citations
,
November 2020 in “medRxiv (Cold Spring Harbor Laboratory)” 5-Alpha-Reductase inhibitors shorten COVID-19 recovery time in men.
3 citations
,
March 2020 in “The Journal of Urology” Older patients sticking to their prostate medication saw lasting health benefits.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
January 2004 in “Pharmaceutical biotechnology” Finasteride effectively inhibits the enzyme steroid 5 alpha-reductase II.
June 2023 in “Frontiers in Cardiovascular Medicine” Using existing drugs for new purposes could be a cost-effective way to treat chest pain and non-clogged heart arteries, with some drugs for lung blood pressure showing promise but needing more testing.
September 2024 in “Frontiers in Neuroendocrinology” 5-alpha reductase inhibitors may help protect the brain and gut in Parkinson's disease.
17 citations
,
October 1994 in “The Journal of Clinical Endocrinology and Metabolism”
12 citations
,
March 1995 in “Journal of the American Chemical Society” Finasteride modifies 5-alpha-reductases through a two-step process, affecting inhibitor potency and possibly causing side effects.
February 2023 in “Reactions Weekly” March 2005 in “The Nurse Practitioner”
25 citations
,
December 2001 in “Expert Opinion on Pharmacotherapy” Potassium channel openers show promise for treating heart disease and other conditions, but more research is needed to fully understand their effects and safety.
June 2011 in “British Journal of Urology” Regulatory challenges make developing combination therapies in urology difficult and costly.
July 2024 in “Reactions Weekly” 53 citations
,
October 2011 in “Psychoneuroendocrinology” Finasteride may help improve certain brain function issues linked to dopamine.
May 2015 in “Endocrinología y nutrición” The conclusion is that adult males with muscle weakness and hormonal imbalances should be tested for Kennedy's disease.
13 citations
,
January 2020 in “Neuroscience” Blocking 5α-reductase can harm memory and brain structure, and increase harmful brain changes in male mice used for Alzheimer's disease research.
24 citations
,
January 1996 in “The Prostate” Finasteride is a safe and effective long-term treatment for prostate enlargement, reducing prostate volume and related symptoms.
184 citations
,
January 2000 in “European Urology” Blocking the enzyme that turns testosterone into DHT can safely and effectively treat enlarged prostate.
September 2006 in “Aktuelle Urologie” Combination drug therapies are more effective for high-risk BPS patients but have more side effects and costs.
23 citations
,
September 2020 in “BMC Cancer” 5α-reductase inhibitors may lower the risk of death from bladder cancer.
February 2026 in “Case Reports in Dermatology” Finasteride can cause melasma, especially in people with darker skin.
January 2025 in “Reactions Weekly” November 2024 in “Reactions Weekly” May 2023 in “Reactions Weekly”
January 2026 in “Yonsei Medical Journal” Finasteride and dutasteride have little effect on Type 2 Diabetes risk.
7 citations
,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism”